Citi has initiated coverage of Viking Therapeutics (NASDAQ:VKTX) with a neutral rating, citing the need for more data for its weight-loss drug candidate VK2735 and high barriers to entry. The ...

B. Riley lowered the firm’s price target on Viking Therapeutics (VKTX) to $96 from $109 and keeps a Buy rating on the shares. The firm remains ...

Stock investors may look back at 2025 as the year of the takeover - one that delivered sizeable gains. "It's going to be a big year," Calamos Investments senior portfolio manager Brandon Nelson ...

Citi analyst David Lebowitz initiated coverage of Viking Therapeutics (VKTX) with a Neutral rating and $38 price target Viking’s VK2735 is an ...

It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their US ...

Fate’s Market in Remus Michigan partners with Great Start Collaborative of Mecosta, Osceola counties to make shopping into a learning experience for children.

Viking Therapeutics stock plunged early Thursday on an earnings report that included mostly incremental updates for its ...

And with a growing number of companies in the GLP-1 space, investors may be losing interest in the stock. Could Viking's ...

CEO Brian Lian highlighted 2024 as an exceptionally busy year, with successful results from four studies, including the Phase 2 VENTURE trial for subcutaneous VK2735, which demonstrated up to 14.7% ...

Viking Therapeutics announces its fourth-quarter financial results after Wednesday's closing bell. Here's a look at the ...

Market uncertainty makes investors nervous about investing in speculative industries. But Wall Street has high hopes for ...